FDC.NS
FDC Limited [FDC.NS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
FDC.NS Stock Summary
Top 10 Correlated Stocks
FDC.NS
In the News
FDC.NS Financial details
Company Rating
Buy
Market Cap
73.36B
Income
2.9B
Revenue
19.16B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
6.37K
Optionable
No
Shortable
Yes
Earnings
23 May 2024
P/E
26.6
Forward P/E
-
PEG
7.19
P/S
3.52
P/B
3.39
P/C
-
P/FCF
-
Quick Ratio
1.7
Current Ratio
3.04
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
17.56
EPS next Y
-
EPS next Q
-
EPS this Y
-8.97%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
3.68%
Revenue last 5Y
10.46%
Revenue Q/Q
-5.8%
EPS Q/Q
15.4%
-
-
-
-
SMA20
3.89%
SMA50
7.36%
SMA100
14.43%
Inst Own
-
Inst Trans
-
ROA
11%
ROE
25%
ROC
0.15%
Gross Margin
65%
Oper. Margin
17%
Profit Margin
13%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
262.0-487.7
52W High
-7.69%
52W Low
+71.58%
RSI
54.7
Rel Volume
0.18
Avg Volume
356.8K
Volume
64.86K
Perf Week
-0.11%
Perf Month
0.74%
Perf Quarter
27.46%
Perf Half Y
16.89%
-
-
-
-
Beta
0.217
-
-
Volatility
1.73%, 11.56%
Prev Close
-0.54%
Price
449.55
Change
-1.2%
FDC.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 62.21 | 77.74 | 78.06 | 90.38 | 107.31 | |
| Net income per share | 9.74 | 13.94 | 17.73 | 12.82 | 11.67 | |
| Operating cash flow per share | 6.45 | 14.55 | 12.18 | 9.58 | 9.32 | |
| Free cash flow per share | 4 | 12.74 | 8.5 | 1.72 | 2.52 | |
| Cash per share | 24.42 | 30.93 | 32.76 | 31.95 | 29.12 | |
| Book value per share | 82.87 | 89.94 | 102.02 | 115.92 | 119.24 | |
| Tangible book value per share | 82.5 | 89.58 | 101.75 | 115.62 | 118.94 | |
| Share holders equity per share | 82.87 | 89.94 | 102.02 | 115.92 | 119.24 | |
| Interest debt per share | 0.1 | 1.05 | 1.02 | 2.06 | 1.95 | |
| Market cap | 28.81B | 33.54B | 48.6B | 43.4B | 42.6B | |
| Enterprise value | 28.62B | 33.39B | 48.44B | 43.35B | 42.65B | |
| P/E ratio | 16.97 | 13.98 | 16.13 | 20.06 | 21.96 | |
| Price to sales ratio | 2.66 | 2.51 | 3.66 | 2.84 | 2.39 | |
| POCF ratio | 25.63 | 13.4 | 23.47 | 26.85 | 27.5 | |
| PFCF ratio | 41.34 | 15.3 | 33.62 | 149.1 | 101.87 | |
| P/B Ratio | 1.99 | 2.17 | 2.8 | 2.22 | 2.15 | |
| PTB ratio | 1.99 | 2.17 | 2.8 | 2.22 | 2.15 | |
| EV to sales | 2.64 | 2.5 | 3.65 | 2.84 | 2.39 | |
| Enterprise value over EBITDA | 11.37 | 9.08 | 13.73 | 15.31 | 14.18 | |
| EV to operating cash flow | 25.45 | 13.34 | 23.39 | 26.81 | 27.53 | |
| EV to free cash flow | 41.06 | 15.24 | 33.51 | 148.91 | 101.97 | |
| Earnings yield | 0.06 | 0.07 | 0.06 | 0.05 | 0.05 | |
| Free cash flow yield | 0.02 | 0.07 | 0.03 | 0.01 | 0.01 | |
| Debt to equity | 0 | 0.01 | 0.01 | 0.02 | 0.01 | |
| Debt to assets | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Net debt to EBITDA | -0.08 | -0.04 | -0.05 | -0.02 | 0.01 | |
| Current ratio | 4.13 | 3.76 | 4.58 | 3.68 | 3.3 | |
| Interest coverage | 183.11 | 88.59 | 107.02 | 86.48 | 51.88 | |
| Income quality | 0.47 | 0.78 | 0.53 | 0.56 | 0.6 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0.06 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Research and developement to revenue | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.38 | -0.12 | -0.3 | -0.82 | -0.73 | |
| Capex to revenue | -0.04 | -0.02 | -0.05 | -0.09 | -0.06 | |
| Capex to depreciation | -1.29 | -0.83 | -1.65 | -3.55 | -2.9 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 134.73 | 167.98 | 201.72 | 182.85 | 176.97 | |
| ROIC | 0.1 | 0.13 | 0.13 | 0.08 | 0.08 | |
| Return on tangible assets | 0.1 | 0.13 | 0.15 | 0.1 | 0.08 | |
| Graham Net | 24.27 | 27.88 | 31.46 | 26.24 | 22.9 | |
| Working capital | 5.61B | 6.81B | 7.3B | 7.28B | 7.15B | |
| Tangible asset value | 14.39B | 15.41B | 17.3B | 19.52B | 19.77B | |
| Net current asset value | 5.45B | 6.62B | 7.11B | 6.86B | 6.65B | |
| Invested capital | 0 | 0.01 | 0.01 | 0.02 | 0.01 | |
| Average receivables | 1.22B | 1.42B | 1.34B | 1.05B | 1.06B | |
| Average payables | 874.66M | 977.36M | 975.66M | 1.07B | 1.58B | |
| Average inventory | 1.67B | 1.92B | 2.12B | 2.6B | 3.17B | |
| Days sales outstanding | 47.16 | 39.33 | 33.98 | 20.76 | 25.61 | |
| Days payables outstanding | 79.27 | 98.49 | 66.06 | 91.3 | 99.35 | |
| Days of inventory on hand | 177.49 | 175.46 | 183.73 | 203.15 | 182.86 | |
| Receivables turnover | 7.74 | 9.28 | 10.74 | 17.58 | 14.25 | |
| Payables turnover | 4.6 | 3.71 | 5.53 | 4 | 3.67 | |
| Inventory turnover | 2.06 | 2.08 | 1.99 | 1.8 | 2 | |
| ROE | 0.12 | 0.16 | 0.17 | 0.11 | 0.1 | |
| Capex per share | -2.45 | -1.82 | -3.68 | -7.85 | -6.8 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 24.67 | 26.21 | 32.33 | 29.4 | 28.14 | |
| Net income per share | 2.46 | 1.85 | 6.62 | 4.22 | 4.87 | |
| Operating cash flow per share | 1.19 | 1.17 | 1.16 | 7.57 | 1.23 | |
| Free cash flow per share | 1.19 | 1.17 | 1.16 | 4.14 | 1.23 | |
| Cash per share | 25.35 | 29.17 | 29.07 | 23.27 | 0 | |
| Book value per share | 114.53 | 119.47 | 119.43 | 119.22 | 0 | |
| Tangible book value per share | 0 | 119.16 | 0 | 118.94 | 0 | |
| Share holders equity per share | 114.53 | 119.47 | 119.43 | 119.22 | 0 | |
| Interest debt per share | 0.07 | 1.78 | 0.06 | 1.55 | 0.06 | |
| Market cap | 44.94B | 42.52B | 51.47B | 63.47B | 64.18B | |
| Enterprise value | 49.14B | 42.57B | 56.3B | 63.5B | 64.18B | |
| P/E ratio | 27.57 | 34.61 | 11.71 | 22.73 | 20.25 | |
| Price to sales ratio | 10.98 | 9.78 | 9.6 | 13.05 | 14.01 | |
| POCF ratio | 227.94 | 218.34 | 267.16 | 50.68 | 321.75 | |
| PFCF ratio | 227.94 | 218.34 | 267.16 | 92.56 | 321.75 | |
| P/B Ratio | 2.36 | 2.15 | 2.6 | 3.22 | 0 | |
| PTB ratio | 2.36 | 2.15 | 2.6 | 3.22 | 0 | |
| EV to sales | 12.01 | 9.79 | 10.5 | 13.06 | 14.01 | |
| Enterprise value over EBITDA | 72.65 | 76.01 | 37.18 | 61.25 | 59.16 | |
| EV to operating cash flow | 249.28 | 218.56 | 292.19 | 50.7 | 321.75 | |
| EV to free cash flow | 249.28 | 218.56 | 292.19 | 92.59 | 321.75 | |
| Earnings yield | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | |
| Free cash flow yield | 0 | 0 | 0 | 0.01 | 0 | |
| Debt to equity | 0 | 0.01 | 0 | 0.01 | 0 | |
| Debt to assets | 0 | 0.01 | 0 | 0.01 | 0 | |
| Net debt to EBITDA | 6.22 | 0.08 | 3.18 | 0.02 | 0 | |
| Current ratio | 0 | 3.3 | 0 | 3.04 | 0 | |
| Interest coverage | 48.28 | 39.92 | 107.3 | 88.52 | 101.13 | |
| Income quality | 0.48 | 0.63 | 0.18 | 1.79 | 0.25 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0.08 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0.04 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | -0.45 | 0 | |
| Capex to revenue | 0 | 0 | 0 | -0.12 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | -2.9 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 79.55 | 70.54 | 133.41 | 106.4 | 0 | |
| ROIC | 0.02 | 0.02 | 0.04 | 0.03 | 0 | |
| Return on tangible assets | 0 | 0.01 | 0 | 0.03 | 0 | |
| Graham Net | 25.35 | 22.94 | 29.07 | 18.55 | 0 | |
| Working capital | 4.21B | 7.15B | 4.82B | 6.55B | 0 | |
| Tangible asset value | 0 | 19.77B | 0 | 19.68B | 0 | |
| Net current asset value | 4.21B | 6.65B | 4.82B | 6.06B | 0 | |
| Invested capital | 0 | 0.01 | 0 | 0.01 | 0 | |
| Average receivables | 745.5M | 625.72M | 625.72M | 808.58M | 808.58M | |
| Average payables | 958.16M | 892.46M | 892.46M | 839.9M | 839.9M | |
| Average inventory | 1.71B | 1.64B | 1.64B | 1.7B | 1.7B | |
| Days sales outstanding | 0 | 25.9 | 0 | 29.92 | 0 | |
| Days payables outstanding | 0 | 104.31 | 0 | 89.26 | 0 | |
| Days of inventory on hand | 0 | 191.99 | 0 | 181.18 | 0 | |
| Receivables turnover | 0 | 3.47 | 0 | 3.01 | 0 | |
| Payables turnover | 0 | 0.86 | 0 | 1.01 | 0 | |
| Inventory turnover | 0 | 0.47 | 0 | 0.5 | 0 | |
| ROE | 0.02 | 0.02 | 0.06 | 0.04 | 0 | |
| Capex per share | 0 | 0 | 0 | -3.42 | 0 |
FDC.NS Frequently Asked Questions
What is FDC Limited stock symbol ?
FDC Limited is a IN stock and trading under the symbol FDC.NS
What is FDC Limited stock quote today ?
FDC Limited stock price is $449.55 today.
Is FDC Limited stock public?
Yes, FDC Limited is a publicly traded company.
Something similar
Company Profile
- Volume Average 356.8K
- Market Capitalization 73.36B
- Employee 6.37K
- CEO Mr. Ameya Ashok Chandavarkar
- Headquarters Mumbai,IN
- IPO Date 2002-07-01
-
Website
https://www.fdcindia.com 
FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others; and oral rehydration salts. It provides specialized formulations primarily under the Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm brand names. The company also offers anti-oxidants, balanced energy drinks, and vitamins and nutraceuticals under the Enerzal, Humyl, Mum Mum 1, Prosoyal, Simyl-LBW, Simyl-MCT, and Zefrich brands. In addition, it provides various active pharmaceutical ingredients. FDC Limited was founded in 1936 and is headquartered in Mumbai, India.
